PT2928477T - Utilização do inibidor da telomerase imetelstat para o tratamento de mielofibrose. - Google Patents

Utilização do inibidor da telomerase imetelstat para o tratamento de mielofibrose.

Info

Publication number
PT2928477T
PT2928477T PT138610084T PT13861008T PT2928477T PT 2928477 T PT2928477 T PT 2928477T PT 138610084 T PT138610084 T PT 138610084T PT 13861008 T PT13861008 T PT 13861008T PT 2928477 T PT2928477 T PT 2928477T
Authority
PT
Portugal
Prior art keywords
myelofibrosis
treatment
telomerase inhibitor
imetelstat
inhibitor imetelstat
Prior art date
Application number
PT138610084T
Other languages
English (en)
Inventor
J Stuart Monic
Kelsey Stephen
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed by Geron Corp filed Critical Geron Corp
Publication of PT2928477T publication Critical patent/PT2928477T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
PT138610084T 2012-12-07 2013-11-15 Utilização do inibidor da telomerase imetelstat para o tratamento de mielofibrose. PT2928477T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P 2013-11-05 2013-11-05

Publications (1)

Publication Number Publication Date
PT2928477T true PT2928477T (pt) 2019-10-25

Family

ID=50883867

Family Applications (3)

Application Number Title Priority Date Filing Date
PT138610084T PT2928477T (pt) 2012-12-07 2013-11-15 Utilização do inibidor da telomerase imetelstat para o tratamento de mielofibrose.
PT181966904T PT3456333T (pt) 2012-12-07 2013-11-15 Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica
PT191877562T PT3646876T (pt) 2012-12-07 2013-11-15 Inibidor da telomerase imetelstat para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT181966904T PT3456333T (pt) 2012-12-07 2013-11-15 Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica
PT191877562T PT3646876T (pt) 2012-12-07 2013-11-15 Inibidor da telomerase imetelstat para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas

Country Status (34)

Country Link
EP (3) EP3456333B8 (pt)
JP (5) JP6433911B2 (pt)
KR (3) KR102294819B1 (pt)
CN (2) CN111617252A (pt)
AP (1) AP2015008504A0 (pt)
AU (4) AU2013356533B2 (pt)
BR (1) BR112015013260A2 (pt)
CA (2) CA3188494A1 (pt)
CL (2) CL2015001530A1 (pt)
CY (2) CY1122169T1 (pt)
DK (3) DK3646876T3 (pt)
EA (1) EA032973B1 (pt)
ES (2) ES2789176T3 (pt)
FI (1) FI3646876T3 (pt)
HK (2) HK1210940A1 (pt)
HR (3) HRP20240624T1 (pt)
HU (3) HUE066402T2 (pt)
IL (2) IL239266B (pt)
LT (3) LT3646876T (pt)
MA (2) MA38193B1 (pt)
ME (1) ME03538B (pt)
MX (3) MX2015007169A (pt)
MY (1) MY180634A (pt)
NZ (1) NZ708920A (pt)
PH (1) PH12015501282A1 (pt)
PL (3) PL3456333T3 (pt)
PT (3) PT2928477T (pt)
RS (2) RS59363B1 (pt)
SG (3) SG11201504383TA (pt)
SI (3) SI3646876T1 (pt)
TN (1) TN2015000249A1 (pt)
UA (3) UA128370C2 (pt)
WO (1) WO2014088785A1 (pt)
ZA (2) ZA201504124B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1778711T1 (sl) 2004-07-02 2017-11-30 Geron Corporation Sinteza zaščitenih 3'-aminonukleozidnih monomerov
HUE042792T2 (hu) * 2013-11-06 2019-07-29 Mayo Found Medical Education & Res Eljárások és anyagok hematológiai, rosszindulatú betegségek kezelésére
RS60645B1 (sr) 2015-04-23 2020-09-30 Geron Corp Postupci za pripremu polinukleotida upotrebom kompozicija multivalentne katjonske soli
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
TW201919705A (zh) * 2017-07-28 2019-06-01 美商健生生物科技公司 治療骨髓增生不良症候群之方法
IL278345B2 (en) * 2018-04-30 2024-05-01 Kartos Therapeutics Inc Cancer treatment methods
KR20210038895A (ko) * 2018-07-31 2021-04-08 제론 코포레이션 텔로머라제 억제제에 의한 치료로부터 이익일 것 같은 환자를 확인하는 방법
JP2023500326A (ja) * 2019-11-04 2023-01-05 ジェロン・コーポレーション 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用
JP2021157248A (ja) * 2020-03-25 2021-10-07 パイオニア株式会社 状況出力装置

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
WO1998028442A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
CA2515000A1 (en) * 2003-01-31 2004-08-19 Jessie L.-S. Au Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
DK3342425T3 (da) 2003-09-09 2020-03-16 Geron Corp Modificerede oligonukleotider til inhibering af telomerase
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
SI1778711T1 (sl) 2004-07-02 2017-11-30 Geron Corporation Sinteza zaščitenih 3'-aminonukleozidnih monomerov
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
PL2101789T3 (pl) * 2006-10-30 2015-05-29 Geron Corp Inhibitor telomerazy skojarzony z gemcytabiną do leczenia nowotworu
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
HRP20191784T1 (hr) 2019-12-27
AU2024203138A1 (en) 2024-07-25
CL2017002156A1 (es) 2018-05-04
CA2892907C (en) 2023-03-21
CN104936602A (zh) 2015-09-23
MA45504A1 (fr) 2020-05-29
ZA202108991B (en) 2023-05-31
IL239266A0 (en) 2015-07-30
KR20210107906A (ko) 2021-09-01
EP3456333B8 (en) 2020-05-13
AU2020267142C1 (en) 2024-08-08
PL3456333T3 (pl) 2020-09-21
CL2015001530A1 (es) 2016-03-28
HK1210940A1 (en) 2016-05-13
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
ES2744790T3 (es) 2020-02-26
EP2928477A4 (en) 2016-09-21
SI2928477T1 (sl) 2019-11-29
WO2014088785A8 (en) 2015-07-16
IL280144A (en) 2021-03-01
EP3646876B1 (en) 2024-02-14
JP6998191B2 (ja) 2022-02-04
JP2018035196A (ja) 2018-03-08
TN2015000249A1 (en) 2016-10-03
JP2022179684A (ja) 2022-12-02
MX2015007169A (es) 2016-03-31
ME03538B (me) 2020-07-20
NZ708920A (en) 2020-08-28
PL3646876T3 (pl) 2024-07-22
JP6433911B2 (ja) 2018-12-05
EP3456333B1 (en) 2020-04-01
RS60401B1 (sr) 2020-07-31
DK2928477T3 (da) 2019-10-07
EP3646876A1 (en) 2020-05-06
KR20230028590A (ko) 2023-02-28
UA128370C2 (uk) 2024-06-26
SG10201802926XA (en) 2018-05-30
AU2020267142B2 (en) 2024-05-16
CY1122169T1 (el) 2020-11-25
KR102294819B1 (ko) 2021-09-01
JP2020041001A (ja) 2020-03-19
KR20150091130A (ko) 2015-08-07
IL239266B (en) 2019-11-28
AP2015008504A0 (en) 2015-06-30
PH12015501282B1 (en) 2015-08-24
EA032973B1 (ru) 2019-08-30
SG10202103341SA (en) 2021-05-28
LT3456333T (lt) 2020-06-25
MY180634A (en) 2020-12-03
KR102662590B1 (ko) 2024-05-03
MX2020003276A (es) 2020-07-20
RS59363B1 (sr) 2019-11-29
ES2789176T3 (es) 2020-10-26
MX2022015437A (es) 2023-01-11
EP2928477A1 (en) 2015-10-14
PL2928477T3 (pl) 2020-03-31
CN104936602B (zh) 2020-07-17
AU2013356533A1 (en) 2014-06-12
ZA201504124B (en) 2017-05-31
UA126015C2 (uk) 2022-08-03
WO2014088785A1 (en) 2014-06-12
MA38193B1 (fr) 2018-12-31
HUE066402T2 (hu) 2024-07-28
HRP20240624T1 (hr) 2024-08-02
EP3456333A1 (en) 2019-03-20
HK1212226A1 (en) 2016-06-10
NZ748134A (en) 2020-10-30
CN111617252A (zh) 2020-09-04
JP2016504307A (ja) 2016-02-12
JP7288098B2 (ja) 2023-06-06
SI3646876T1 (sl) 2024-07-31
DK3646876T3 (da) 2024-05-06
MA38193A1 (fr) 2017-12-29
FI3646876T3 (fi) 2024-05-14
LT3646876T (lt) 2024-05-10
HUE049858T2 (hu) 2020-11-30
SI3456333T1 (sl) 2020-10-30
PT3646876T (pt) 2024-05-15
PT3456333T (pt) 2020-06-01
CA2892907A1 (en) 2014-06-12
CA3188494A1 (en) 2014-06-12
AU2020267142A1 (en) 2020-12-03
CY1123206T1 (el) 2021-10-29
PH12015501282A1 (en) 2015-08-24
MA45504B1 (fr) 2021-10-29
DK3456333T3 (da) 2020-05-18
EP2928477B1 (en) 2019-07-24
SG11201504383TA (en) 2015-07-30
LT2928477T (lt) 2019-10-10
AU2013356533B2 (en) 2018-09-27
AU2018282364A1 (en) 2019-05-23
EA201590878A1 (ru) 2016-04-29
BR112015013260A2 (pt) 2018-02-06
UA117116C2 (uk) 2018-06-25
JP2022050537A (ja) 2022-03-30

Similar Documents

Publication Publication Date Title
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
HK1210174A1 (en) Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases
HK1207583A1 (en) Use of biotin for the treatment of multiple sclerosis
HUE045098T2 (hu) A telomerázinhibitor imetelstat alkalmazása mielofibrózis kezelésére
EP2826473A4 (en) NEW USE OF PATCHOULOL
ZA201406082B (en) Use of ccr3-inhibitors
EP2968204A4 (en) TREATMENT WITH A PHOSPHODIESTERASE HEMMER
HRP20181879T1 (hr) Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
HK1203054A1 (en) Dinuceloside polyphosphates for the treatment of pain
PL2882880T3 (pl) Obróbka materiałów zawierających mangan
EP2895504A4 (en) TRPV3 AGONISTS FOR THE TREATMENT OF SKIN DISEASES
AP2015008272A0 (en) Treatment of wax
SG11201403246PA (en) Treatment of manganese-containing materials
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-
HK1200094A1 (en) Use of immunomodulators for the treatment of cancer
GB201318433D0 (en) Candidate for the treatment of epilepsy